We submit the Audited Results as at 31.03.2026. We earlier uploaded in the outcome of Board Meeting but somehow results were not included. While revising it, we are not allowed with the ....
TRANSPEK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.0 pts less than Nifty Microcap 250 and 11.1 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transpek Industry Limited has reported audited standalone and consolidated results for FY26 (year ended March 2026). Revenue from operations declined to ₹62,120 lakhs from ₹64,985 lakhs in the previous year, representing a 4.4% decrease. Net profit fell to ₹4,565 lakhs from ₹4,874 lakhs, a decline of approximately 6.3%. EPS declined from ₹87.26 to ₹81.73 per share. The company declared a dividend of ₹20 per equity share (200% on face value of ₹10). Total comprehensive income dropped significantly to ₹3,330 lakhs from ₹7,975 lakhs due to negative fair value changes in equity instruments. The auditors (Bansi S. Mehta & Co.) issued an unmodified opinion with no concerns raised. The company has a wholly-owned subsidiary, Transpek Creative Chemistry Private Limited.
Revenue and profit declines indicate challenging market conditions in the chemicals business. However, the dividend declaration and strong cash generation (₹7,847 lakhs from operations) show the company remains financially stable. The sharp drop in comprehensive income is primarily due to mark-to-market losses on investments rather than operational issues.